Fight against antimicrobial resistance
Authors:
J. Spížek
Authors‘ workplace:
Mikrobiologický ústav AV ČR, v. v. i., Praha
Published in:
Epidemiol. Mikrobiol. Imunol. 67, 2018, č. 2, s. 74-80
Category:
Review Article
Overview
Antimicrobial and antibiotic resistance is ever increasing and the fight against it is a battle that can never be won. Nevertheless, some possibilities exist to improve this situation, at least in part. The present review article discusses some approaches that can be used to control microbial resistance. Possible strategies are (1) designing new vaccines against resistant bacterial strains; (2) investigation of the potential of both traditional and non-traditional sources of natural substances for use as new antibiotics; (3) search for genes specifying biosynthesis of antibiotics; (4) use of forgotten natural compounds and their transformation, and (5) investigation of new antibiotic targets in pathogenic bacteria. Particular attention is paid to the search for new compounds that would be able to inhibit pathogenic bacteria resistant to existing antibiotics.
Keywords:
sepsis – septic shock – organ dysfunction – definition – criteria
Sources
1. Bennett JW. What is an Antibiotic? Norfolk, UK: Caister Academic Press; 2015:1–18.
2. Leung LM, Fondrie WE, Doi Y, et al. Identification of the ESKAPE pathogens by mass spectrometric analysis of microbial membrane glycolipids. Sci Rep, 2017;7(1):6403.
3. Prichystal J, Schug KA, Lemr K, et al. Structural Analysis of Natural Products. Anal Chem, 2016;88(21):10338–10346.
4. Davies SC, Fowler T, Watson J, et al. Annual report of the Chief medical officer: infection and the rise of antimicrobial resistance. Lancet, 2013;381(9878):1606–1609.
5. Walsh CT, Wencewicz TA. Prospects for new antibiotics: a molecule-centered perspective. J Antibiot, 2014;67(1):7–22.
6. Newman DJ, Cragg GM. Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod, 2016;79(3):629–661.
7. Mishra RPN, Oviedo-Orta E, Prachi P, et al. Vaccines and antibiotic resistance. Cur Opin Mircobiol, 2012;15(5):596–602.
8. Jerse AE, Bash MC, Russell MW. Vaccines against gonorrhea: Current status and future challenges. Vaccine, 2014;32(14):1579–1587.
9. Finco O, Rappuoli R. Designing vaccines for the twenty-first century society. Front Immunol, 2014;5(číslo článku 12).
10. Bagnoli F, Baudner B, Mishra RPN, et al. Designing the next generation of vaccines for global public health. Omics J Integrat Biol, 2011;15(9):545–566.
11. Spizek J, Novotna J, Rezanka T, et al. Do we need new antibiotics? The search for new targets and new compounds. J Ind Microbiol Biotechnol, 2010;37(12):1241–1248.
12. Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J Antibiot, 2013;66(10):571–591.
13. Boucher HW, Talbot GH, Benjamin DK, Jr, et al. 10 x '20 Progress-development of new drugs active against Gram-negative bacilli: an update from the infectious diseases society of America. Clin Infect Dis, 2013;56(12):1685–1694.
14. Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence, 2013;4(2):185–191.
15. Daniel R. The soil metagenome – a rich resource for the discovery of novel natural products. Cur Opin Biotechnol, 2004;15(3):199–204.
16. Hopwood DA. Therapeutic treasures from the deep. Nature Chem Biol, 2007;3(8):457–458.
17. Subramani R, Aalbersberg W. Marine actinomycetes: An ongoing source of novel bioactive metabolites. Microbiol Res, 2012;167(10):571–580.
18. Fenical W, Jensen PR. Developing a new resource for drug discovery: marine actinomycete bacteria. Nat Chem Biol, 2006;2(12):666–673.
19. Doshi GV, Aggarwal GV, Martis EA, et al. Novel antibiotics from marine sources. Int J Pharmaceut Sci Nanotechnol, 2011;4:1446–1461.
20. Hu G-P, Yuan J, Sun L, et al. Statistical research on marine natural products based on data obtained between 1985 and 2008. Mar Drugs, 2011;9(4):514–525.
21. Gulder TAM, Moore BS. Chasing the treasures of the sea - bacterial marine natural products. Cur Opin Microbiol, 2009;12(3):252–260.
22. Kamjam M, Sivalingam P, Deng ZX, et al. Deep Sea Actinomycetes and Their Secondary Metabolites. Frontiers in Microbiology, 2017;8 (article number 160).
23. Bachmann BO, Van Lanen SG, Baltz RH. Microbial genome mining for accelerated natural products discovery: is a renaissance in the making? J Ind Microbiol Biotechnol, 2014;41(2):175–184.
24. Katz L, Baltz RH. Natural product discovery: past, present, and future. J Ind Microbiol Biotechnol, 2016;43(2–3):155–176.
25. Demain AL. Importance of microbial natural products and the need to revitalize their discovery. J Ind Microbiol Biotechnol, 2014;41(2):185–201.
26. Baltz RH. Strain improvement in actinomycetes in the postgenomic era. J Ind Microbiol Biotechnol, 2011;38(6):657–666.
27. Baltz RH. Function of MbtH homologs in nonribosomal peptide biosynthesis and applications in secondary metabolite discovery. J Ind Microbiol Biotechnol, 2011;38(11):1747–1760.
28. Baltz RH. MbtH homology codes to identify gifted microbes for genome mining. J Ind Microbiol Biotechnol, 2014;41(2):357–369.
29. Baltz RH. Antibiotic discovery from actinomycetes: will a renais-sance follow the decline and fall? SIM News, 2005;55:186–196.
30. WHO. Critically important antimicrobials for human medicine, 5th revision 2016. World Health Organization, Geneva, Switzerland, 2017.
31. Uchiyama I. MBGD: microbial genome database for comparative analysis. Nucleic Acids Res, 2003;31(1):58–62.
32. Pulcini C, Bush K, Craig WA, et al. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis, 2012;54(2):268–274.
33. Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Res Updates, 2011;14(2):118–124.
34. Bakheet TM, Doig AJ. Properties and identification of antibiotic drug targets. BMC Bioinformatics, 2010;11(číslo článku 195).
35. Amabile-Cuevas CF. Antibiotic resistance: from Darwin to Lederberg to Keynes. Microb Drug Resist, 2013;19(2):73–87.
36. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev, 2010;74(3):417–433.
37. Watve MG, Tickoo R, Jog MM, et al. How many antibiotics are produced by the genus Streptomyces? Arch Microbiol, 2001;176(5):386–390.
Labels
Hygiene and epidemiology Medical virology Clinical microbiologyArticle was published in
Epidemiology, Microbiology, Immunology
2018 Issue 2
Most read in this issue
- Streptococcal toxic shock syndrome – a life-threatening condition caused by various streptococcal species
- Bacteremia due to Staphylococcus aureus – the importance of appropriate management
- Fight against antimicrobial resistance
- Updated Czech guidelines for the laboratory diagnosis of Clostridium difficile infections